ALT - Altimmune, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Altimmune, Inc.

910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240-654-1450
http://www.altimmune.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchel B. SayareExec. Chairman109.9kN/A1948
Mr. William J. EnrightPres, CEO & Director333.88kN/A1963
Dr. Sybil TaskerChief Medical Officer and SVP of Clinical R&D216.79kN/A1963
Mr. William Michael BrownActing CFO & Principal Accounting OfficerN/AN/A1982
Mr. Bertrand Georges Ph.D.Chief Technology OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Corporate Governance

Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.